CAPTRUST Financial Advisors
AIMT

CAPTRUST Financial Advisors’s Aimmune Therapeutics AIMT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$3K – 3629
2020
Q3 		$3K Sell
100
-165
-62% -$3.51K ﹤0.01% 2708
2020
Q2 		$4K Buy
+265
New +$4.5K ﹤0.01% 2472

CAPTRUST Financial Advisors's AIMT Position: Q4 2020 in Review

CAPTRUST Financial Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 100 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in AIMT in Q2 2020 and held it in 2 quarters. The position peaked at $4K in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • CAPTRUST Financial Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 100 Aimmune Therapeutics shares in Q4 2020, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Aimmune Therapeutics in Q2 2020 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Aimmune Therapeutics position peaked at $4K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.